---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-013085"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2025-03-17T23:59:59+00:00"
generated_at: "2026-05-24T14:53:09.465753+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sangamo FY2024 net loss $97.9M; FDA clears ST-503 IND; Fabry BLA path to Accelerated Approval

## Summary
- FY2024 net loss $97.9M ($0.49/share) vs $257.8M ($1.48) in 2023; revenue $57.8M vs $176.2M.
- Cash $41.9M at Dec 31, 2024; with $10.1M ATM proceeds and $5M Pfizer payment, funds operations into mid-Q2 2025.
- FDA cleared IND for ST-503 (chronic neuropathic pain); patient enrollment expected mid-2025; preliminary efficacy data Q4 2026.
- FDA agreed to Accelerated Approval for isaralgagene civaparvovec in Fabry using Phase 1/2 data; BLA submission H2 2025.
- License agreements with Genentech (Aug 2024) and Astellas (Dec 2024) for STAC-BBB capsid; $20M upfront from Astellas.

## SEC filing metadata
- accession: 0001628280-25-013085
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2025-03-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000162828025013085/0001628280-25-013085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000162828025013085/sgmo-20250317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-013085
- JSON: https://secwatch.observer/filing/0001628280-25-013085.json
- Plain text: https://secwatch.observer/filing/0001628280-25-013085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.